Genelux Corporation is a clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for patients with aggressive and difficult-to-treat solid tumors. The company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary modified strain of the vaccinia virus designed for systemic and intratumoral delivery, with primary clinical focus on platinum-resistant/refractory ovarian cancer. Pipeline assets are derived from Genelux's proprietary CHOICE discovery platform, an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic candidates. Founded in 2001 and headquartered in Westlake Village, California, Genelux IPO'd on Nasdaq under ticker GNLX in January 2023.
Genelux is publicly traded
IPO'd on January 26, 2023
This company is no longer available on our private secondary market. Shares can be traded publicly under GNLX.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2001
Employees
20–30
Total Funding
$66M
3 rounds
Total raised $66M across 3 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 05-21-2026
Latest Round
Type
Post-IPO Equity (Public Offering)
Date
May 23, 2024
Amount
Undisclosed
Valuation
—
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| May 23, 2024 | Post-IPO Equity (Public Offering) | Undisclosed | — | |
| May 15, 2023 | Private Placement (PIPE) | $33M | — | |
| January 26, 2023 | IPO | $15M | — |
Thomas Zindrick
Chairman, President & Chief Executive Officer
Matt Pulisic
Chief Financial Officer
Jason Litten
Chief Medical Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Replimune
Clinical-stage company developing intratumoral HSV-1-based oncolytic immunotherapies (RP1, RP2, RP3) for solid tumors.
Candel Therapeutics
Late clinical-stage biopharma developing adenovirus- and HSV-based oncolytic viral immunotherapies for prostate, pancreatic, and lung cancers.
CG Oncology
Clinical-stage biotech advancing cretostimogene grenadenorepvec (CG0070), an intravesical oncolytic adenovirus immunotherapy for non-muscle invasive bladder cancer.
Oncolytics Biotech
Clinical-stage biotech developing pelareorep, an intravenously delivered reovirus-based oncolytic immunotherapy for breast, pancreatic, and other solid tumors.
Imugene
Clinical-stage immuno-oncology company with an oncolytic virotherapy platform (CF33/Vaxinia) and other cancer immunotherapy candidates.
Targovax
Clinical-stage immuno-oncology company developing oncolytic virus immunotherapies (ONCOS-102) for solid tumors including mesothelioma and melanoma.
Yes, Genelux is publicly traded under the ticker symbol GNLX on the NASDAQ. The company went public in January 26, 2023.
Genelux trades under the ticker symbol GNLX on the NASDAQ. It began trading in January 26, 2023.
Genelux (GNLX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker GNLX to place an order.
Genelux went public in January 26, 2023 via ipo. Genelux is publicly traded on the Nasdaq Capital Market under ticker GNLX following its January 26, 2023 IPO, which priced 2,500,000 shares at $6.00/share for gross proceeds of approximately $15.0 million. The company has since raised additional capital through a $33M private placement (May 2023) and a follow-on common stock and warrants offering (May 2024). FY2025 results disclosed revenue of ~$0.01M and a net loss of ~$32.1M as the company advances Olvi-Vec into late-stage clinical trials.
Genelux raised $66M across 3 disclosed funding rounds prior to its public listing.
Genelux is headquartered in Westlake Village, CA, USA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.